Table 3.

Prevalence (%) and numbers of participants with impaired fasting glucose and/or non–diabetic hyperglycemia in a high risk population of 10,000*.

BMI (kg/m2)
Age band (yrs)		<20	20<25	25–<30	30–<35	35–<40	40–<45	45+	Total
39–44	%	40	6.6	11	11	13	32	31	14
	n	5	61	79	185	98	34	16	479
45–49	%	0	9.2	18	11	17	14	22	14
	n	12	65	125	246	143	58	23	672
50–54	%	0	7.9	17	15	23	34	25	18
	n	8	101	251	490	215	77	44	1,186
55–59	%	18	12	19	21	31	38	23	22
	n	11	126	348	568	179	80	35	1,347
60–64	%	6.3	17	25	22	27	33	33	24
	n	16	197	508	743	244	79	45	1,832
65–69	%	0	24	25	29	29	28	38	27
	n	13	245	694	827	272	69	29	2,149
70–74	%	13	31	37	29	43	36	53	34
	n	8	177	467	447	119	33	15	1,266
75–79	%	0	33	35	39	39	50	0	37
	n	1	117	325	220	66	14	0	743
80+	%	100	38	42	51	57	75	0	45
	n	1	72	139	87	23	4	0	326
Total	%	9.3	21	27	24	28	32	30	25
	n	75	1,161	2,936	3,813	1,359	448	207	10,000

^*Prevalences (%) are for a combined category of participants potentially suitable for randomisation to trial as they had IFG (fasting plasma glucose ≥6.1–<7.0 mmol/mol) and/or non–diabetic hyperglycemia (NDH; HbA1c ≥6%–<6.5% (≥42 to <48 mmol/mol)). Each cell shows overall numbers of participants (n) screened in each age & BMI category (total n = 10,000), with prevalence (%) of categories potentially suitable for randomisation into trial for each cell. All data are based on the first baseline sample.